 PLYMOUTH MEETING, Pa. , Dec. 22, 2022 PRNewswire -- Harmony Biosciences Holdings, Inc. Harmony or the Company Nasdaq: HRMY, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that President and CEO, John C. 